Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05611892 · ClinicalTrials.gov registry record
Biodistribution and Pathophysiology Study of 18F-Fluorodeoxysorbitol (18F-FDS) in Diseased Patients
A clinical trial of Inflammatory Disease and Invasive Fungal Infections, sponsored by Johns Hopkins University.
- Completed
- Registry status
- 16
- Enrollment target
- 1
- Study location
NCT05611892: Completed study of Inflammatory Disease and Invasive Fungal Infections, sponsored by Johns Hopkins University.
NCT05611892 is a study of Inflammatory Disease and Invasive Fungal Infections that has completed, run by Johns Hopkins University. The registered enrollment target is 16 participants, below the 1,276-participant average among 5 other Inflammatory Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05611892, a study of Inflammatory Disease and Invasive Fungal Infections, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, the investigators will assess the hypothesis that this new positron emission tomography (PET) radiopharmaceutical, 18F-Fluorodeoxysorbitol (18F-FDS), will specifically localize at sites of Gram-negative bacterial due to Enterobacterales and invasive mold infections (e.g. invasive aspergillosis/mucormycosis).
Primary Outcome
Reconstruction of the PET data will be performed by means of iterative reconstruction (IR) by the ordered subset-expectation-maximization method with CT attenuation correction. Volumes of interest will be drawn on fused PET and CT images across different body compartments and comparison.
Conditions Studied
Interventions
- COMBINATION_PRODUCT 18F-FDS PET/CT
Study Locations (1)
Maryland
- Johns Hopkins Medical Institutions - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2022-12-22 |
| Est. Completion | 2025-10-28 |
What the finished NCT05611892 record still lists
NCT05611892 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,276-participant average among 5 other Inflammatory Disease trials with a reported enrollment target (99% lower).
The record links to 4 conditions, with Inflammatory Disease appearing as the primary indexed condition, and to 1 intervention - of which 18F-FDS PET/CT is the first listed.
NCT05611892 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT05611892 about?
NCT05611892 is a clinical study titled "Biodistribution and Pathophysiology Study of 18F-Fluorodeoxysorbitol (18F-FDS) in Diseased Patients". In this study, the investigators will assess the hypothesis that this new positron emission tomography (PET) radiopharmaceutical, 18F-Fluorodeoxysorbitol (18F-FDS), will specifically localize at sites of Gram-negative bacterial due to Enterobacterales and invasive mold infections (e.g. invasive aspe...
What is the current status of trial NCT05611892?
This trial is currently completed. The enrollment target is 16 participants. The study started on 2022-12-22. Estimated completion is 2025-10-28.
What conditions does trial NCT05611892 study?
This clinical trial studies the following conditions: Inflammatory Disease, Invasive Fungal Infections, Enterobacterial Infections, Oncologic Disease.
What interventions are being tested in trial NCT05611892?
The interventions under investigation include: 18F-FDS PET/CT (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05611892?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05611892 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammatory Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
RECRUITING
-
The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
RECRUITING
-
A Clinical Study to Assess the Efficacy of Cannabigerol in Patients with Active Rheumatoid Arthritis.
ACTIVE NOT RECRUITING · NA
-
Feasibility Study to Assess a Trans-nasal Intestinal Potential Difference Probe
ACTIVE NOT RECRUITING · NA
-
The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI